Jirtle R L, Haag J D, Ariazi E A, Gould M N
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710.
Cancer Res. 1993 Sep 1;53(17):3849-52.
The monoterpenes represent a potentially new class of breast cancer therapeutic agents. We have shown that d-limonene induces the regression of advanced rat mammary adenocarcinomas. These regressing tumors have an increased cellular concentration of both the mannose-6-phosphate/insulin-like growth factor II receptors and transforming growth factor beta 1. The terpene-induced regression of mammary tumors may result in part from the mitoinhibitory and differentiation properties of active transforming growth factor beta 1. Furthermore, the activation of transforming growth factor beta 1 in these tumors is likely to be facilitated by the increased concentration of the mannose-6-phosphate/insulin-like growth factor II receptors in the mammary tumor cells. Tumors not responding to terpene therapy lacked a rise in the mannose-6-phosphate/insulin-like growth factor II receptor level which may relate to the fact that this gene is hemizygous due to maternal imprinting.
单萜类化合物代表了一类潜在的新型乳腺癌治疗药物。我们已经表明，d-柠檬烯可诱导晚期大鼠乳腺腺癌消退。这些消退的肿瘤中，甘露糖-6-磷酸/胰岛素样生长因子II受体和转化生长因子β1的细胞浓度均有所增加。萜类化合物诱导乳腺肿瘤消退可能部分是由于活性转化生长因子β1的有丝分裂抑制和分化特性。此外，乳腺肿瘤细胞中甘露糖-6-磷酸/胰岛素样生长因子II受体浓度的增加可能会促进这些肿瘤中转化生长因子β1的激活。对萜类治疗无反应的肿瘤，其甘露糖-6-磷酸/胰岛素样生长因子II受体水平没有升高，这可能与该基因由于母本印记而半合子有关。
